Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Aug;74(4):502–507. doi: 10.1038/bjc.1996.393

Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.

S Withoff 1, W N Keith 1, A J Knol 1, J C Coutts 1, S F Hoare 1, N H Mulder 1, E G de Vries 1
PMCID: PMC2074676  PMID: 8761362

Abstract

A panel of doxorubicin-resistant sublines of the human small-cell lung carcinoma cell line GLC4 displays decreasing DNA topoisomerase II alpha (TopoII alpha) mRNA levels with increasing resistance. In the present study we describe how this decrease may be regulated. No significant differences in TopoII alpha mRNA stability or gene arrangement were found, using mRNA slot-blotting and Southern blotting, in the most resistant cell line compared with the parental cell line. To investigate if TopoII alpha gene copy loss contributed to the mRNA decrease, fluorescence in situ hybridisation using a TopoII alpha-specific probe was performed. During doxorubicin resistance development, the composition of the population in each cell line shifted with increasing resistance, from a population in which most cells contain three TopoII alpha gene copies (GLC4) to a population in which most cells contain only two copies. A partial revertant of the most resistant cell line displayed a shift back to the original situation. We conclude that the TopoII alpha gene copy number decrease per cell line is in good agreement with the decreased TopoII alpha mRNA and protein levels, and TopoII activity levels in these cell lines which were described previously.

Full text

PDF
502

Images in this article

504Figure 3
on p.504
504Figure 2
on p.504

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austin C. A., Sng J. H., Patel S., Fisher L. M. Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta. 1993 Mar 20;1172(3):283–291. doi: 10.1016/0167-4781(93)90215-y. [DOI] [PubMed] [Google Scholar]
  2. Beck W. T., Danks M. K., Wolverton J. S., Kim R., Chen M. Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul. 1993;33:113–127. doi: 10.1016/0065-2571(93)90012-3. [DOI] [PubMed] [Google Scholar]
  3. Binaschi M., Giaccone G., Gazdar A. F., De Isabella P., Ricotti G. C., Capranico G., Zunino F. Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line. J Natl Cancer Inst. 1992 Nov 18;84(22):1710–1716. doi: 10.1093/jnci/84.22.1710. [DOI] [PubMed] [Google Scholar]
  4. Coutts J., Plumb J. A., Brown R., Keith W. N. Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer. 1993 Oct;68(4):793–800. doi: 10.1038/bjc.1993.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. D'Arpa P., Liu L. F. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta. 1989 Dec 17;989(2):163–177. doi: 10.1016/0304-419x(89)90041-3. [DOI] [PubMed] [Google Scholar]
  6. Davies S. M., Robson C. N., Davies S. L., Hickson I. D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem. 1988 Nov 25;263(33):17724–17729. [PubMed] [Google Scholar]
  7. Dexter D. L., Leith J. T. Tumor heterogeneity and drug resistance. J Clin Oncol. 1986 Feb;4(2):244–257. doi: 10.1200/JCO.1986.4.2.244. [DOI] [PubMed] [Google Scholar]
  8. Drake F. H., Hofmann G. A., Bartus H. F., Mattern M. R., Crooke S. T., Mirabelli C. K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989 Oct 3;28(20):8154–8160. doi: 10.1021/bi00446a029. [DOI] [PubMed] [Google Scholar]
  9. Eijdems E. W., De Haas M., Coco-Martin J. M., Ottenheim C. P., Zaman G. J., Dauwerse H. G., Breuning M. H., Twentyman P. R., Borst P., Baas F. Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer. 1995 Mar 3;60(5):676–684. doi: 10.1002/ijc.2910600518. [DOI] [PubMed] [Google Scholar]
  10. Fry A. M., Chresta C. M., Davies S. M., Walker M. C., Harris A. L., Hartley J. A., Masters J. R., Hickson I. D. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 1991 Dec 15;51(24):6592–6595. [PubMed] [Google Scholar]
  11. Hann S. R., Eisenman R. N. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol. 1984 Nov;4(11):2486–2497. doi: 10.1128/mcb.4.11.2486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Husain I., Mohler J. L., Seigler H. F., Besterman J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 1994 Jan 15;54(2):539–546. [PubMed] [Google Scholar]
  13. Jenkins J. R., Ayton P., Jones T., Davies S. L., Simmons D. L., Harris A. L., Sheer D., Hickson I. D. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 1992 Nov 11;20(21):5587–5592. doi: 10.1093/nar/20.21.5587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kallioniemi O. P., Kallioniemi A., Kurisu W., Thor A., Chen L. C., Smith H. S., Waldman F. M., Pinkel D., Gray J. W. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321–5325. doi: 10.1073/pnas.89.12.5321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Keith W. N., Douglas F., Wishart G. C., McCallum H. M., George W. D., Kaye S. B., Brown R. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer. 1993;29A(10):1469–1475. doi: 10.1016/0959-8049(93)90022-8. [DOI] [PubMed] [Google Scholar]
  16. Kimura K., Saijo M., Ui M., Enomoto T. Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J Biol Chem. 1994 Jan 14;269(2):1173–1176. [PubMed] [Google Scholar]
  17. Lönn U., Lönn S., Nilsson B., Stenkvist B. Intratumoral heterogeneity for amplified genes in human breast carcinoma. Int J Cancer. 1994 Jul 1;58(1):40–45. doi: 10.1002/ijc.2910580108. [DOI] [PubMed] [Google Scholar]
  18. Meijer C., Mulder N. H., Timmer-Bosscha H., Peters W. H., de Vries E. G. Combined in vitro modulation of adriamycin resistance. Int J Cancer. 1991 Oct 21;49(4):582–586. doi: 10.1002/ijc.2910490419. [DOI] [PubMed] [Google Scholar]
  19. Meijer C., Mulder N. H., Timmer-Bosscha H., Zijlstra J. G., de Vries E. G. Role of free radicals in an adriamycin-resistant human small cell lung cancer cell line. Cancer Res. 1987 Sep 1;47(17):4613–4617. [PubMed] [Google Scholar]
  20. Murphy D. S., McHardy P., Coutts J., Mallon E. A., George W. D., Kaye S. B., Brown R., Keith W. N. Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer. 1995 Feb 20;64(1):18–26. doi: 10.1002/ijc.2910640106. [DOI] [PubMed] [Google Scholar]
  21. Müller M., Meijer C., Zaman G. J., Borst P., Scheper R. J., Mulder N. H., de Vries E. G., Jansen P. L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):13033–13037. doi: 10.1073/pnas.91.26.13033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nederlof P. M., van der Flier S., Raap A. K., Tanke H. J. Quantification of inter- and intra-nuclear variation of fluorescence in situ hybridization signals. Cytometry. 1992;13(8):831–838. doi: 10.1002/cyto.990130805. [DOI] [PubMed] [Google Scholar]
  23. Pedersen-Bjergaard J., Johansson B., Philip P. Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation. Cancer Genet Cytogenet. 1994 Aug;76(1):50–55. doi: 10.1016/0165-4608(94)90071-x. [DOI] [PubMed] [Google Scholar]
  24. Pommier Y., Leteurtre F., Fesen M. R., Fujimori A., Bertrand R., Solary E., Kohlhagen G., Kohn K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994;12(5):530–542. doi: 10.3109/07357909409021413. [DOI] [PubMed] [Google Scholar]
  25. Ritke M. K., Yalowich J. C. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol. 1993 Dec 3;46(11):2007–2020. doi: 10.1016/0006-2952(93)90643-b. [DOI] [PubMed] [Google Scholar]
  26. Tan K. B., Dorman T. E., Falls K. M., Chung T. D., Mirabelli C. K., Crooke S. T., Mao J. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res. 1992 Jan 1;52(1):231–234. [PubMed] [Google Scholar]
  27. Tan K. B., Mattern M. R., Eng W. K., McCabe F. L., Johnson R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 1989 Nov 15;81(22):1732–1735. doi: 10.1093/jnci/81.22.1732. [DOI] [PubMed] [Google Scholar]
  28. Tsuji T., Mimura Y., Maeda K., Ida M., Sasaki K., Shinozaki F. Numerical aberrations of chromosome 17 detected by FISH with DNA-specific probe in oral tumors. Anticancer Res. 1994 Sep-Oct;14(5A):1689–1693. [PubMed] [Google Scholar]
  29. Versantvoort C. H., Withoff S., Broxterman H. J., Kuiper C. M., Scheper R. J., Mulder N. H., de Vries E. G. Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer. 1995 May 4;61(3):375–380. doi: 10.1002/ijc.2910610317. [DOI] [PubMed] [Google Scholar]
  30. Withoff S., Smit E. F., Meersma G. J., van den Berg A., Timmer-Bosscha H., Kok K., Postmus P. E., Mulder N. H., de Vries E. G., Buys C. H. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. Lab Invest. 1994 Jul;71(1):61–66. [PubMed] [Google Scholar]
  31. Woessner R. D., Chung T. D., Hofmann G. A., Mattern M. R., Mirabelli C. K., Drake F. H., Johnson R. K. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res. 1990 May 15;50(10):2901–2908. [PubMed] [Google Scholar]
  32. Zijlstra J. G., de Vries E. G., Mulder N. H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1987 Apr 1;47(7):1780–1784. [PubMed] [Google Scholar]
  33. Zini N., Santi S., Ognibene A., Bavelloni A., Neri L. M., Valmori A., Mariani E., Negri C., Astaldi-Ricotti G. C., Maraldi N. M. Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp Cell Res. 1994 Feb;210(2):336–348. doi: 10.1006/excr.1994.1046. [DOI] [PubMed] [Google Scholar]
  34. de Jong S., Kooistra A. J., de Vries E. G., Mulder N. H., Zijlstra J. G. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res. 1993 Mar 1;53(5):1064–1071. [PubMed] [Google Scholar]
  35. de Jong S., Zijlstra J. G., Mulder N. H., de Vries E. G. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol. 1991;28(6):461–464. doi: 10.1007/BF00685823. [DOI] [PubMed] [Google Scholar]
  36. de Jong S., Zijlstra J. G., de Vries E. G., Mulder N. H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1990 Jan 15;50(2):304–309. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES